Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 4:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Psychoses Clear all
Completed Phase 3 Interventional

A Study to Evaluate Efficacy and Safety of Bitopertin in Participants With Persistent, Predominant Negative Symptoms of Schizophrenia

NCT01192880
View directory record Official record
Conditions
Schizophrenia
Interventions
Placebo, Bitopertin, Antipsychotics
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
625 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
27
States / cities
Costa Mesa, California • Escondido, California • Granada Hills, California + 24 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2017 · Synced Sep 10, 2026, 4:15 PM EDT
Completed No phase listed Observational

Genetic Study of Schizophrenia

NCT00001486
View directory record Official record
Conditions
Schizoaffective Disorder, Schizophrenia
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 55 Years
Enrollment
4,914 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1995
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 10, 2026, 4:15 PM EDT
Terminated Phase 3 Interventional Results available

Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia

NCT03121586
View directory record Official record
Conditions
Schizophrenia
Interventions
Pimavanserin
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
995 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
32
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 27 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2025 · Synced Sep 10, 2026, 4:15 PM EDT
Terminated Phase 2 Interventional

A Clinical Trial of PRAX-114 in Participants With Post-Traumatic Stress Disorder

NCT05260541
View directory record Official record
Conditions
Post-traumatic Stress Disorder, Post Traumatic Stress Disorder, Stress Disorder, Stress Disorders, Post-Traumatic, Trauma and Stressor Related Disorders, Mental Disorder
Interventions
60 mg PRAX-114 or 40 mg PRAX-114, Placebo, 40 mg PRAX-114
Drug
Lead sponsor
Praxis Precision Medicines
Industry
Eligibility
18 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
17
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2022 · Synced Sep 10, 2026, 4:15 PM EDT
Completed Not applicable Interventional

Examining Risk Factors for Atypical Antipsychotic Metabolic Side Effects

NCT00815854
View directory record Official record
Conditions
Schizophrenia
Interventions
Folic Acid, Placebo
Dietary Supplement · Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 90 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 20, 2019 · Synced Sep 10, 2026, 4:15 PM EDT
Withdrawn Not applicable Interventional

Long Acting Paliperidone in Dually Diagnosed People With Schizophrenia: An Open-label Pilot Study

NCT01584466
View directory record Official record
Conditions
Schizophrenia
Interventions
Paliperidone
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 64 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 16, 2022 · Synced Sep 10, 2026, 4:15 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness

NCT01149551
View directory record Official record
Conditions
Schizophrenia, Bipolar Disorder
Interventions
Not listed
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
9,356 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
25
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • No. Little Rock, Arkansas + 22 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2015 · Synced Sep 10, 2026, 4:15 PM EDT
Completed Not applicable Interventional

Cognitive Behavioral Therapy (CBT) Study Evaluating the Updating of Persecutory Beliefs

NCT04748679
View directory record Official record
Conditions
Schizophrenia; Psychosis, Persecutory Delusion
Interventions
Worry Intervention, Befriending
Behavioral
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 14, 2024 · Synced Sep 10, 2026, 4:15 PM EDT
Completed Phase 3 Interventional Results available

Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia

NCT00706654
View directory record Official record
Conditions
Schizophrenia
Interventions
Aripiprazole depot 300 or 400 mg, Aripiprazole 10-30 mg orally, Aripiprazole depot 25 or 50 mg, Placebo depot, Placebo tablets
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
937 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
39
States / cities
Cerritos, California • Escondido, California • Garden Grove, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 10, 2026, 4:15 PM EDT
Completed Phase 3 Interventional

A Study of RO4917838 in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (NN25307)

NCT01235520
View directory record Official record
Conditions
Schizophrenia
Interventions
Placebo, RO4917838
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
595 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
30
States / cities
Little Rock, Arkansas • Buena Park, California • Cerritos, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2015 · Synced Sep 10, 2026, 4:15 PM EDT
Completed Phase 4 Interventional

Treatment of Behavioral Symptoms in Alzheimer's Disease

NCT00009217
View directory record Official record
Conditions
Alzheimer's Disease, Psychosis, Agitation
Interventions
Haloperidol-Haloperidol, Haloperidol-Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
50 Years to 95 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 23, 2016 · Synced Sep 10, 2026, 4:15 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate TV-46000 as Maintenance Treatment in Adult and Adolescent Participants With Schizophrenia

NCT03503318
View directory record Official record
Conditions
Schizophrenia
Interventions
TV-46000, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
13 Years to 65 Years
Enrollment
544 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
73
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Anaheim, California + 58 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2023 · Synced Sep 10, 2026, 4:15 PM EDT
Completed Phase 1 Interventional

A Multiple Ascending Dose Trial of CVL-231 in Subjects With Schizophrenia

NCT04136873
View directory record Official record
Conditions
Schizophrenia
Interventions
CVL-231, Matching Placebo
Drug
Lead sponsor
Cerevel Therapeutics, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
5
States / cities
Bentonville, Arkansas • Little Rock, Arkansas • Lemon Grove, California + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2021 · Synced Sep 10, 2026, 4:15 PM EDT
Completed No phase listed Observational

Molecular Genetics of Schizophrenia

NCT00006418
View directory record Official record
Conditions
Schizophrenia
Interventions
DNA collection
Procedure
Lead sponsor
Endeavor Health
Other
Eligibility
18 Years and older
Enrollment
10,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
9
States / cities
Irvine, California • Denver, Colorado • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2014 · Synced Sep 10, 2026, 4:15 PM EDT
Completed Not applicable Interventional

Family-Directed Cognitive Adaptation Program for Individuals With Schizophrenia

NCT00434980
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
Interventions
Family-Directed Cognitive Adaptation Program
Behavioral
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
2
States / cities
Boston, Massachusetts • Jamaica Plain, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Sep 10, 2026, 4:15 PM EDT
Recruiting Phase 2 Interventional

Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With Schizophrenia

NCT07680946
View directory record Official record
Conditions
Schizophrenia
Interventions
Ublituximab
Drug
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Little Rock, Arkansas • Richardson, Texas
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 10, 2026, 4:15 PM EDT
Completed Phase 4 Interventional

Improving Substance Use and Clinical Outcomes in Heavy Cannabis Users With Quetiapine

NCT01153490
View directory record Official record
Conditions
Cannabis Dependence
Interventions
Behavioral Intervention
Behavioral
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 65 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Glen Oaks, New York • Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Apr 16, 2018 · Synced Sep 10, 2026, 4:15 PM EDT
Completed Phase 4 Interventional Results available

Exenatide Weekly Injections as an Adjunctive Treatment in Patients With Schizophrenia

NCT02417142
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Exenatide, Placebo
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 13, 2022 · Synced Sep 10, 2026, 4:15 PM EDT
Recruiting Not applicable Interventional

A Novel Peer-Delivered Recovery-Focused Suicide Prevention Intervention for Veterans With Serious Mental Illness

NCT05537376
View directory record Official record
Conditions
Psychotic Disorders, Bipolar Disorders, Suicidal Ideation, Suicide, Attempted
Interventions
SUicide Prevention by Peers Offering Recovery Tactics
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 10, 2026, 4:15 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Assess the Effects of RO6889450 (Ralmitaront) in Participants With Schizophrenia or Schizoaffective Disorder and Negative Symptoms

NCT03669640
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
RO6889450, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 55 Years
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
28
States / cities
Bellflower, California • Garden Grove, California • Glendale, California + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2024 · Synced Sep 10, 2026, 4:15 PM EDT
Completed Phase 3 Interventional

New Antipsychotic Strategies: Quetiapine and Risperidone vs. Fluphenazine in Treatment Resistant Schizophrenia

NCT00161018
View directory record Official record
Conditions
Schizophrenia
Interventions
Quetiapine, Risperidone, Fluphenazine
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 18, 2019 · Synced Sep 10, 2026, 4:15 PM EDT
Terminated No phase listed Observational

Risks for Insulin Resistance and Metabolic Syndrome Between Major Depressive Disorder (MDD) or MDD With Psychotic Features

NCT01310140
View directory record Official record
Conditions
Major Depressive Disorder, Major Depressive Disorder w/ Psychotic Features, Metabolic Syndrome
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 12, 2017 · Synced Sep 10, 2026, 4:15 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Neuroimaging Studies of Neurophysiological Phenotypes in Schizophrenia

NCT01036568
View directory record Official record
Conditions
Schizophrenia, Psychosis
Interventions
Not listed
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 62 Years
Enrollment
121 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2013
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 4, 2018 · Synced Sep 10, 2026, 4:15 PM EDT
Completed Not applicable Interventional

Improving Antipsychotic Adherence Among Patients With Serious Mental Illness

NCT00057135
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
Interventions
Unit of use medication packaging, Mailed reminders to patient when medication refills are due, Note to Mental Health Provider when refill is overdue, Aligning all prescriptions to fall due on same date
Behavioral · Procedure
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
5
States / cities
San Diego, California • Hines, Illinois • East Orange, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2015 · Synced Sep 10, 2026, 4:15 PM EDT